This is a Validated Antibody Database (VAD) review about rhesus mac.. MAMU-A3, based on 49 published articles (read how Labome selects the articles), using MAMU-A3 antibody in all methods. It is aimed to help Labome visitors find the most suited MAMU-A3 antibody. Please note the number of articles fluctuates since newly identified citations are added and citations for discontinued catalog numbers are removed regularly.
MAMU-A3 synonym: A4; Mamu-A; Mamu-A1; Mamu-A4

BioLegend
mouse monoclonal (W6/32)
  • flow cytometry; human; 1:100; loading ...; fig s4b
BioLegend MAMU-A3 antibody (BioLegend, 311406) was used in flow cytometry on human samples at 1:100 (fig s4b). Cell Rep (2022) ncbi
mouse monoclonal (W6/32)
  • flow cytometry; human; fig s1
BioLegend MAMU-A3 antibody (Biolegend, W6/32) was used in flow cytometry on human samples (fig s1). Mol Ther Methods Clin Dev (2022) ncbi
mouse monoclonal (W6/32)
  • mass cytometry; human; loading ...; fig 5b
BioLegend MAMU-A3 antibody (Biolegend, 311402) was used in mass cytometry on human samples (fig 5b). Cell Rep (2022) ncbi
mouse monoclonal (W6/32)
  • flow cytometry; human; 1:100; loading ...; fig 2c, 5f, s3e
BioLegend MAMU-A3 antibody (Biolegend, 311406) was used in flow cytometry on human samples at 1:100 (fig 2c, 5f, s3e). Proc Natl Acad Sci U S A (2022) ncbi
mouse monoclonal (W6/32)
  • immunohistochemistry - paraffin section; human; 1:100; fig 6
BioLegend MAMU-A3 antibody (Biolegend, 311402) was used in immunohistochemistry - paraffin section on human samples at 1:100 (fig 6). NPJ Regen Med (2021) ncbi
mouse monoclonal (W6/32)
  • flow cytometry; human; loading ...; fig 2b
BioLegend MAMU-A3 antibody (Biolegend, W6/32) was used in flow cytometry on human samples (fig 2b). BMC Biol (2021) ncbi
mouse monoclonal (W6/32)
  • flow cytometry; human; 1:200; loading ...; fig 3d
BioLegend MAMU-A3 antibody (BioLegend, 311410) was used in flow cytometry on human samples at 1:200 (fig 3d). J Immunother Cancer (2021) ncbi
mouse monoclonal (W6/32)
  • other; mouse; 1:100; fig 3c
BioLegend MAMU-A3 antibody (Biolegend, 311410) was used in other on mouse samples at 1:100 (fig 3c). Cell (2021) ncbi
mouse monoclonal (W6/32)
  • flow cytometry; human; loading ...; fig 2e, 2f, 2g
BioLegend MAMU-A3 antibody (Biolegend, 311410) was used in flow cytometry on human samples (fig 2e, 2f, 2g). Proc Natl Acad Sci U S A (2021) ncbi
mouse monoclonal (W6/32)
  • ELISA; human
BioLegend MAMU-A3 antibody (BioLegend, 311402) was used in ELISA on human samples . Science (2021) ncbi
mouse monoclonal (W6/32)
  • flow cytometry; human; fig 5a
BioLegend MAMU-A3 antibody (Biolegend, 311426) was used in flow cytometry on human samples (fig 5a). Sci Rep (2021) ncbi
mouse monoclonal (W6/32)
  • flow cytometry; human; 1:75; loading ...; fig 2b
BioLegend MAMU-A3 antibody (BioLegend, W6/32) was used in flow cytometry on human samples at 1:75 (fig 2b). Nature (2020) ncbi
mouse monoclonal (W6/32)
  • flow cytometry; human; 1:100; loading ...; fig s20c
BioLegend MAMU-A3 antibody (Biolegend, 311403) was used in flow cytometry on human samples at 1:100 (fig s20c). Nat Commun (2020) ncbi
mouse monoclonal (W6/32)
  • flow cytometry; human; loading ...; fig 2e
BioLegend MAMU-A3 antibody (Biolegend, 311413) was used in flow cytometry on human samples (fig 2e). Stem Cell Res Ther (2020) ncbi
mouse monoclonal (W6/32)
  • flow cytometry; human; loading ...
BioLegend MAMU-A3 antibody (BioLegend, W6/32) was used in flow cytometry on human samples . JCI Insight (2019) ncbi
mouse monoclonal (W6/32)
  • flow cytometry; mouse; loading ...; fig s5b
BioLegend MAMU-A3 antibody (BioLegend, 311426) was used in flow cytometry on mouse samples (fig s5b). Nat Immunol (2019) ncbi
mouse monoclonal (W6/32)
  • blocking or activating experiments; human; 10 ug/ml; fig 4i
BioLegend MAMU-A3 antibody (Biolegend, 311427) was used in blocking or activating experiments on human samples at 10 ug/ml (fig 4i). Cancer Cell (2019) ncbi
mouse monoclonal (W6/32)
  • flow cytometry; human; loading ...; fig s8
BioLegend MAMU-A3 antibody (BioLegend, W6/32) was used in flow cytometry on human samples (fig s8). Nat Commun (2019) ncbi
mouse monoclonal (W6/32)
  • flow cytometry; human; loading ...; fig 3
BioLegend MAMU-A3 antibody (BioLegend, 311410) was used in flow cytometry on human samples (fig 3). J Virol (2018) ncbi
mouse monoclonal (W6/32)
  • flow cytometry; human; fig 5a
BioLegend MAMU-A3 antibody (Biolegend, 311425) was used in flow cytometry on human samples (fig 5a). Stem Cells Transl Med (2018) ncbi
mouse monoclonal (W6/32)
  • flow cytometry; human; loading ...; fig s1
BioLegend MAMU-A3 antibody (Biolegend, W6/32) was used in flow cytometry on human samples (fig s1). JCI Insight (2018) ncbi
mouse monoclonal (W6/32)
  • flow cytometry; human; loading ...; fig 2l
BioLegend MAMU-A3 antibody (BioLegend, 311426) was used in flow cytometry on human samples (fig 2l). Cancer Res (2018) ncbi
mouse monoclonal (W6/32)
  • flow cytometry; human; 1:50; fig 2a
BioLegend MAMU-A3 antibody (BioLegend, W6/32) was used in flow cytometry on human samples at 1:50 (fig 2a). Nat Immunol (2018) ncbi
mouse monoclonal (W6/32)
  • flow cytometry; human; loading ...; fig 5b
BioLegend MAMU-A3 antibody (BioLegend, w6/32) was used in flow cytometry on human samples (fig 5b). J Virol (2018) ncbi
mouse monoclonal (W6/32)
  • flow cytometry; human; loading ...; fig s1b
BioLegend MAMU-A3 antibody (BioLegend, W6/32) was used in flow cytometry on human samples (fig s1b). Nature (2017) ncbi
mouse monoclonal (W6/32)
  • blocking or activating experiments; human; loading ...
BioLegend MAMU-A3 antibody (BioLegend, w6/32) was used in blocking or activating experiments on human samples . J Immunol (2017) ncbi
mouse monoclonal (W6/32)
  • immunocytochemistry; human; 1:500; loading ...; fig 1a
BioLegend MAMU-A3 antibody (BioLegend, W6/32) was used in immunocytochemistry on human samples at 1:500 (fig 1a). J Cell Sci (2017) ncbi
mouse monoclonal (W6/32)
  • flow cytometry; human; fig e6a
In order to report preclinical studies using a CRISPR-based methodology to target hematopoietic stem cells to treat beta-haemoglobinopathies, BioLegend MAMU-A3 antibody (BioLegend, W6/32) was used in flow cytometry on human samples (fig e6a). Nature (2016) ncbi
mouse monoclonal (W6/32)
  • flow cytometry; human; loading ...; fig 3e, 3f
BioLegend MAMU-A3 antibody (BioLegend, W6/32) was used in flow cytometry on human samples (fig 3e, 3f). Proc Natl Acad Sci U S A (2016) ncbi
mouse monoclonal (W6/32)
  • flow cytometry; human; loading ...
BioLegend MAMU-A3 antibody (BioLegend, W6/32) was used in flow cytometry on human samples . J Exp Med (2016) ncbi
mouse monoclonal (W6/32)
  • flow cytometry; human; fig 1a
In order to assess the effects of platelet-derived ectosomes on natural killer cells, BioLegend MAMU-A3 antibody (BioLegend, W6/32) was used in flow cytometry on human samples (fig 1a). J Immunol (2016) ncbi
mouse monoclonal (W6/32)
  • flow cytometry; human; fig s2
In order to determine modulation of presentation of cell surfaced calreticulin by alpha-integrin function and expression, BioLegend MAMU-A3 antibody (Biolegend, W6/32) was used in flow cytometry on human samples (fig s2). Cell Death Dis (2016) ncbi
mouse monoclonal (W6/32)
  • flow cytometry; human; loading ...; fig 3c
BioLegend MAMU-A3 antibody (Biolegend, W6/32) was used in flow cytometry on human samples (fig 3c). J Immunol (2016) ncbi
mouse monoclonal (W6/32)
  • flow cytometry; human; loading ...; tbl 1
BioLegend MAMU-A3 antibody (BioLegend, W6/32) was used in flow cytometry on human samples (tbl 1). J Immunol (2016) ncbi
mouse monoclonal (W6/32)
  • flow cytometry; human; fig s6b
In order to test if AML patients treated decitabine have induced expression of cancer testis antigens, BioLegend MAMU-A3 antibody (BioLegend, W6/32) was used in flow cytometry on human samples (fig s6b). Oncotarget (2016) ncbi
mouse monoclonal (W6/32)
  • flow cytometry; human; 1:100; fig 2
BioLegend MAMU-A3 antibody (Biolegend, W6/32) was used in flow cytometry on human samples at 1:100 (fig 2). Nat Commun (2016) ncbi
mouse monoclonal (W6/32)
  • flow cytometry; human; fig 5
BioLegend MAMU-A3 antibody (Biolegend, 311404) was used in flow cytometry on human samples (fig 5). Br J Cancer (2015) ncbi
mouse monoclonal (W6/32)
  • immunohistochemistry; human; 1:50
In order to investigate the dynamics and characteristics of natural killer cell types in the human ocular mucosal surface in situ during infection with group D human adenoviruses, BioLegend MAMU-A3 antibody (Biolegend, W6/32) was used in immunohistochemistry on human samples at 1:50. Mucosal Immunol (2016) ncbi
mouse monoclonal (W6/32)
  • other; human; fig 2
In order to characterize capabilities and potentials of extracellular vesicle (EV) array, BioLegend MAMU-A3 antibody (BioLegend, 311402) was used in other on human samples (fig 2). J Extracell Vesicles (2015) ncbi
mouse monoclonal (W6/32)
  • flow cytometry; human; tbl 1
BioLegend MAMU-A3 antibody (Biolegend, W.6.32) was used in flow cytometry on human samples (tbl 1). Cancer Immunol Immunother (2015) ncbi
mouse monoclonal (W6/32)
  • flow cytometry; human; fig 1
  • immunocytochemistry; human; fig 3
BioLegend MAMU-A3 antibody (BioLegend, W6/32) was used in flow cytometry on human samples (fig 1) and in immunocytochemistry on human samples (fig 3). Cancer Immunol Res (2015) ncbi
mouse monoclonal (W6/32)
  • ELISA; human; fig s1
BioLegend MAMU-A3 antibody (Biolegend, 311402) was used in ELISA on human samples (fig s1). MAbs (2015) ncbi
mouse monoclonal (W6/32)
  • blocking or activating experiments; human; 15 ug/ml; fig 4
BioLegend MAMU-A3 antibody (BioLegend, W6/32) was used in blocking or activating experiments on human samples at 15 ug/ml (fig 4). Vaccine (2015) ncbi
mouse monoclonal (W6/32)
  • flow cytometry; human; fig 1
BioLegend MAMU-A3 antibody (Biolegend, W6/32) was used in flow cytometry on human samples (fig 1). J Infect Dis (2015) ncbi
mouse monoclonal (W6/32)
  • flow cytometry; human
BioLegend MAMU-A3 antibody (BioLegend, W6/32) was used in flow cytometry on human samples . J Leukoc Biol (2014) ncbi
mouse monoclonal (W6/32)
  • immunohistochemistry; mouse; 1:50; fig 3
BioLegend MAMU-A3 antibody (BioLegend, 311402) was used in immunohistochemistry on mouse samples at 1:50 (fig 3). Mol Cancer Res (2015) ncbi
mouse monoclonal (W6/32)
  • western blot; human; fig 2
In order to study the effect of HCV infection on IFN-induced expression of MHC class I genes, BioLegend MAMU-A3 antibody (BioLegend, W6/32) was used in western blot on human samples (fig 2). Gastroenterology (2014) ncbi
mouse monoclonal (W6/32)
  • flow cytometry; human
BioLegend MAMU-A3 antibody (Biolegend, 311403) was used in flow cytometry on human samples . PLoS ONE (2013) ncbi
mouse monoclonal (W6/32)
  • flow cytometry; human; loading ...; fig 2d
In order to assess how different concentrations of IFN-gamma affect dendritic cells, BioLegend MAMU-A3 antibody (BioLegend, W6/32) was used in flow cytometry on human samples (fig 2d). J Leukoc Biol (2014) ncbi
Articles Reviewed
  1. Taniguchi H, Caeser R, Chavan S, Zhan Y, Chow A, Manoj P, et al. WEE1 inhibition enhances the antitumor immune response to PD-L1 blockade by the concomitant activation of STING and STAT1 pathways in SCLC. Cell Rep. 2022;39:110814 pubmed publisher
  2. Poletto E, Colella P, Pimentel Vera L, Khan S, Tomatsu S, Baldo G, et al. Improved engraftment and therapeutic efficacy by human genome-edited hematopoietic stem cells with Busulfan-based myeloablation. Mol Ther Methods Clin Dev. 2022;25:392-409 pubmed publisher
  3. van der Heide V, Jangra S, Cohen P, Rathnasinghe R, Aslam S, Aydillo T, et al. Limited extent and consequences of pancreatic SARS-CoV-2 infection. Cell Rep. 2022;38:110508 pubmed publisher
  4. Wolpaw A, Grossmann L, Dessau J, Dong M, Aaron B, Brafford P, et al. Epigenetic state determines inflammatory sensing in neuroblastoma. Proc Natl Acad Sci U S A. 2022;119: pubmed publisher
  5. Han E, Qian H, Jiang B, Figetakis M, Kosyakova N, Tellides G, et al. A therapeutic vascular conduit to support in vivo cell-secreted therapy. NPJ Regen Med. 2021;6:40 pubmed publisher
  6. Zhu Y, Xie J, Shi J. Rac1/ROCK-driven membrane dynamics promote natural killer cell cytotoxicity via granzyme-induced necroptosis. BMC Biol. 2021;19:140 pubmed publisher
  7. Wu S, Xiao Y, Wei J, Xu X, Jin X, Hu X, et al. MYC suppresses STING-dependent innate immunity by transcriptionally upregulating DNMT1 in triple-negative breast cancer. J Immunother Cancer. 2021;9: pubmed publisher
  8. Nathan A, Rossin E, Kaseke C, Park R, Khatri A, Koundakjian D, et al. Structure-guided T cell vaccine design for SARS-CoV-2 variants and sarbecoviruses. Cell. 2021;: pubmed publisher
  9. Zhang Y, Chen Y, Li Y, Huang F, Luo B, Yuan Y, et al. The ORF8 protein of SARS-CoV-2 mediates immune evasion through down-regulating MHC-Ι. Proc Natl Acad Sci U S A. 2021;118: pubmed publisher
  10. Hsiue E, Wright K, Douglass J, Hwang M, Mog B, Pearlman A, et al. Targeting a neoantigen derived from a common TP53 mutation. Science. 2021;371: pubmed publisher
  11. Wang Y, Mohseni M, Grauel A, Diez J, Guan W, Liang S, et al. SHP2 blockade enhances anti-tumor immunity via tumor cell intrinsic and extrinsic mechanisms. Sci Rep. 2021;11:1399 pubmed publisher
  12. Yamamoto K, Venida A, Yano J, Biancur D, Kakiuchi M, Gupta S, et al. Autophagy promotes immune evasion of pancreatic cancer by degrading MHC-I. Nature. 2020;581:100-105 pubmed publisher
  13. Mosaheb M, Dobrikova E, Brown M, Yang Y, Cable J, Okada H, et al. Genetically stable poliovirus vectors activate dendritic cells and prime antitumor CD8 T cell immunity. Nat Commun. 2020;11:524 pubmed publisher
  14. Queckborner S, Syk Lundberg E, Gemzell Danielsson K, Davies L. Endometrial stromal cells exhibit a distinct phenotypic and immunomodulatory profile. Stem Cell Res Ther. 2020;11:15 pubmed publisher
  15. Merola J, Reschke M, Pierce R, Qin L, Spindler S, Baltazar T, et al. Progenitor-derived human endothelial cells evade alloimmunity by CRISPR/Cas9-mediated complete ablation of MHC expression. JCI Insight. 2019;4: pubmed publisher
  16. Verma V, Shrimali R, Ahmad S, Dai W, Wang H, Lu S, et al. PD-1 blockade in subprimed CD8 cells induces dysfunctional PD-1+CD38hi cells and anti-PD-1 resistance. Nat Immunol. 2019;20:1231-1243 pubmed publisher
  17. Dangaj D, Bruand M, Grimm A, Ronet C, Barras D, Duttagupta P, et al. Cooperation between Constitutive and Inducible Chemokines Enables T Cell Engraftment and Immune Attack in Solid Tumors. Cancer Cell. 2019;35:885-900.e10 pubmed publisher
  18. Pavel Dinu M, Wiebking V, Dejene B, Srifa W, Mantri S, Nicolas C, et al. Gene correction for SCID-X1 in long-term hematopoietic stem cells. Nat Commun. 2019;10:1634 pubmed publisher
  19. Heusinger E, Deppe K, Sette P, Krapp C, Kmiec D, Kluge S, et al. Preadaptation of Simian Immunodeficiency Virus SIVsmm Facilitated Env-Mediated Counteraction of Human Tetherin by Human Immunodeficiency Virus Type 2. J Virol. 2018;92: pubmed publisher
  20. Liao Y, Ivanova L, Sivalenka R, Plumer T, Zhu H, Zhang X, et al. Efficacy of Human Placental-Derived Stem Cells in Collagen VII Knockout (Recessive Dystrophic Epidermolysis Bullosa) Animal Model. Stem Cells Transl Med. 2018;7:530-542 pubmed publisher
  21. Liu R, Merola J, Manes T, Qin L, Tietjen G, Lopez Giraldez F, et al. Interferon-γ converts human microvascular pericytes into negative regulators of alloimmunity through induction of indoleamine 2,3-dioxygenase 1. JCI Insight. 2018;3: pubmed publisher
  22. Jung Y, Cackowski F, Yumoto K, Decker A, Wang J, Kim J, et al. CXCL12γ Promotes Metastatic Castration-Resistant Prostate Cancer by Inducing Cancer Stem Cell and Neuroendocrine Phenotypes. Cancer Res. 2018;78:2026-2039 pubmed publisher
  23. Barkal A, Weiskopf K, Kao K, Gordon S, Rosental B, Yiu Y, et al. Engagement of MHC class I by the inhibitory receptor LILRB1 suppresses macrophages and is a target of cancer immunotherapy. Nat Immunol. 2018;19:76-84 pubmed publisher
  24. Mwimanzi F, Toyoda M, Mahiti M, Mann J, Martin J, Bangsberg D, et al. Resistance of Major Histocompatibility Complex Class B (MHC-B) to Nef-Mediated Downregulation Relative to that of MHC-A Is Conserved among Primate Lentiviruses and Influences Antiviral T Cell Responses in HIV-1-Infected Individuals. J Virol. 2018;92: pubmed publisher
  25. Burr M, Sparbier C, Chan Y, Williamson J, Woods K, Beavis P, et al. CMTM6 maintains the expression of PD-L1 and regulates anti-tumour immunity. Nature. 2017;549:101-105 pubmed publisher
  26. Zhang X, Lian X, Dai Z, Zheng H, Chen X, Zheng Y. ?3-Deletion Isoform of HLA-A11 Modulates Cytotoxicity of NK Cells: Correlations with HIV-1 Infection of Cells. J Immunol. 2017;199:2030-2042 pubmed publisher
  27. Johnson D, Wayt J, Wilson J, Donaldson J. Arf6 and Rab22 mediate T cell conjugate formation by regulating clathrin-independent endosomal membrane trafficking. J Cell Sci. 2017;130:2405-2415 pubmed publisher
  28. Dever D, Bak R, Reinisch A, Camarena J, Washington G, Nicolas C, et al. CRISPR/Cas9 β-globin gene targeting in human haematopoietic stem cells. Nature. 2016;539:384-389 pubmed publisher
  29. Albanese M, Tagawa T, Bouvet M, Maliqi L, Lutter D, Hoser J, et al. Epstein-Barr virus microRNAs reduce immune surveillance by virus-specific CD8+ T cells. Proc Natl Acad Sci U S A. 2016;113:E6467-E6475 pubmed
  30. Tagawa T, Albanese M, Bouvet M, Moosmann A, Mautner J, Heissmeyer V, et al. Epstein-Barr viral miRNAs inhibit antiviral CD4+ T cell responses targeting IL-12 and peptide processing. J Exp Med. 2016;213:2065-80 pubmed publisher
  31. Sadallah S, Schmied L, Eken C, Charoudeh H, Amicarella F, Schifferli J. Platelet-Derived Ectosomes Reduce NK Cell Function. J Immunol. 2016;197:1663-71 pubmed publisher
  32. Liu C, LeClair P, Monajemi M, Sly L, Reid G, Lim C. α-Integrin expression and function modulates presentation of cell surface calreticulin. Cell Death Dis. 2016;7:e2268 pubmed publisher
  33. Reches A, Nachmani D, Berhani O, Duev Cohen A, Shreibman D, Ophir Y, et al. HNRNPR Regulates the Expression of Classical and Nonclassical MHC Class I Proteins. J Immunol. 2016;196:4967-76 pubmed publisher
  34. Li H, Borrego F, Nagata S, Tolnay M. Fc Receptor-like 5 Expression Distinguishes Two Distinct Subsets of Human Circulating Tissue-like Memory B Cells. J Immunol. 2016;196:4064-74 pubmed publisher
  35. Srivastava P, Paluch B, Matsuzaki J, James S, Collamat Lai G, Blagitko Dorfs N, et al. Induction of cancer testis antigen expression in circulating acute myeloid leukemia blasts following hypomethylating agent monotherapy. Oncotarget. 2016;7:12840-56 pubmed publisher
  36. Johnson D, Estrada M, Salgado R, Sanchez V, Doxie D, Opalenik S, et al. Melanoma-specific MHC-II expression represents a tumour-autonomous phenotype and predicts response to anti-PD-1/PD-L1 therapy. Nat Commun. 2016;7:10582 pubmed publisher
  37. Thuring C, Follin E, Geironson L, Freyhult E, Junghans V, Harndahl M, et al. HLA class I is most tightly linked to levels of tapasin compared with other antigen-processing proteins in glioblastoma. Br J Cancer. 2015;113:952-62 pubmed publisher
  38. Yawata N, Selva K, Liu Y, Tan K, Lee A, Siak J, et al. Dynamic change in natural killer cell type in the human ocular mucosa in situ as means of immune evasion by adenovirus infection. Mucosal Immunol. 2016;9:159-70 pubmed publisher
  39. Jørgensen M, Bæk R, Varming K. Potentials and capabilities of the Extracellular Vesicle (EV) Array. J Extracell Vesicles. 2015;4:26048 pubmed publisher
  40. Boerman G, van Ostaijen Ten Dam M, Kraal K, Santos S, Ball L, Lankester A, et al. Role of NKG2D, DNAM-1 and natural cytotoxicity receptors in cytotoxicity toward rhabdomyosarcoma cell lines mediated by resting and IL-15-activated human natural killer cells. Cancer Immunol Immunother. 2015;64:573-83 pubmed publisher
  41. Bradley S, Chen Z, Melendez B, Talukder A, Khalili J, Rodríguez Cruz T, et al. BRAFV600E Co-opts a Conserved MHC Class I Internalization Pathway to Diminish Antigen Presentation and CD8+ T-cell Recognition of Melanoma. Cancer Immunol Res. 2015;3:602-9 pubmed publisher
  42. Nambiar J, Clarke A, Shim D, Mabon D, Tian C, Windloch K, et al. Potent neutralizing anti-CD1d antibody reduces lung cytokine release in primate asthma model. MAbs. 2015;7:638-50 pubmed publisher
  43. Tomimaru Y, Mishra S, Safran H, Charpentier K, Martin W, De Groot A, et al. Aspartate-β-hydroxylase induces epitope-specific T cell responses in hepatocellular carcinoma. Vaccine. 2015;33:1256-66 pubmed publisher
  44. Boltjes A, van Montfoort N, Biesta P, Op den Brouw M, Kwekkeboom J, van der Laan L, et al. Kupffer cells interact with hepatitis B surface antigen in vivo and in vitro, leading to proinflammatory cytokine production and natural killer cell function. J Infect Dis. 2015;211:1268-78 pubmed publisher
  45. Chao Y, Kaliaperumal N, Chretien A, Tang S, Lee B, Poidinger M, et al. Human plasmacytoid dendritic cells regulate IFN-α production through activation-induced splicing of IL-18Rα. J Leukoc Biol. 2014;96:1037-46 pubmed publisher
  46. Jung Y, Wang J, Lee E, McGee S, Berry J, Yumoto K, et al. Annexin 2-CXCL12 interactions regulate metastatic cell targeting and growth in the bone marrow. Mol Cancer Res. 2015;13:197-207 pubmed publisher
  47. Kang W, Sung P, Park S, Yoon S, Chang D, Kim S, et al. Hepatitis C virus attenuates interferon-induced major histocompatibility complex class I expression and decreases CD8+ T cell effector functions. Gastroenterology. 2014;146:1351-60.e1-4 pubmed publisher
  48. Fuentes T, Appleby N, Tsay E, Martinez J, Bailey L, Hasaniya N, et al. Human neonatal cardiovascular progenitors: unlocking the secret to regenerative ability. PLoS ONE. 2013;8:e77464 pubmed publisher
  49. Svajger U, Obermajer N, Jeras M. IFN-?-rich environment programs dendritic cells toward silencing of cytotoxic immune responses. J Leukoc Biol. 2014;95:33-46 pubmed publisher